Hydroxamate sulfonamides as CD23 shedding inhibitors

Details for Australian Patent Application No. 2004249496 (hide)

Owner Celltech R & D Limited

Inventors Sharpe, Andrew; Watson, Robert John; Dyke, Hazel Joan; Allen, Daniel Rees; Owen, David Alan

Agent Watermark

Pub. Number AU-A-2004249496

PCT Pub. Number WO2004/113312

Priority 0325834.0 05.11.03 GB; 0314244.5 19.06.03 GB

Filing date 18 June 2004

Wipo publication date 29 December 2004

International Classifications

C07D 295/22 (2006.01) Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

A61K 31/496 (2006.01) - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene

A61P 37/08 (2006.01) Drugs for immunological or allergic disorders

Event Publications

12 January 2006 PCT application entered the National Phase

  PCT publication WO2004/113312 Priority application(s): WO2004/113312

14 February 2008 Assignment before Grant

  Celltech R&D Limited The application has been assigned to UCB Pharma S.A.

14 January 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004249497-Interferon gamma-like protein

2004249495-Thienopyridone derivatives as kinase inhibitors